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Background: Biomarkers play an important role in the diagnosis and risk stratiﬁcation of patients with ischemic
heart disease. Currently, troponin continues as the reference biomarker in acute coronary syndromes. However,
there are other biomarkers that have shown additional value in improving sensitivity and prognostic informa-
tion. Several promising molecules are reviewed, some related to cardiomyocyte structure and others working
as inﬂammatory and renal function markers.
Conclusions: Althoughmany biomarkers have been shown useful in some studies, further prospective studies are
needed to establish their accurate usefulness in routine clinical practice.© 2015 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the past years biomarkers have become a fundamental tool for
the evaluation and management of numerous diseases. Cardiology, and
more speciﬁcally, acute coronary syndrome, is no stranger to this. Cur-
rently, several molecules have demonstrated their value in improving
the diagnosis and prognostic classiﬁcation of patients with acute myo-
cardial infarction. However, available biomarkers are not perfect and in-
terpretation requires careful consideration of the speciﬁc clinical
scenario [1].
This review aims to analyze the value of biomarkers in acute coro-
nary syndromes (ACS) with a special look on new candidates that
could contribute in the near future to the role reserved at present almost
exclusively to troponins.
2. Brief historical overview: from AST to troponin
The use of biomarkers in the diagnosis of acutemyocardial infarction
(AMI) begins in 1954 when Karmen et al. ﬁrst reported elevation of as-
partate aminotransferase (AST) in the serum of patients with AMI [2].
Later, limitations of AST as a biomarker were recognized due to its
lack of speciﬁcity for myocardial tissue. One year later,Wroblewski pro-
posed the use of lactate dehydrogenase (LDH) in the diagnosis of AMI
[3].artin).
is an open access article under the CThe 1960s marked the beginning of creatine kinase (CK) as a better
biomarker as it was demonstrated to be more cardiac-speciﬁc and
clinically useful due to its kinetics after AMI [4]. In the following years
thedevelopment of new laboratory techniqueswas essential to describe
the CK-MB isoenzymeas themolecule that showed thehighest diagnos-
tic accuracy [5]. TheWorld Health Organization (WHO) ofﬁcially recog-
nized themajor role of CK-MB and other enzymedeterminations in AMI
diagnosis in 1979, when diagnostic criteria included demonstration of
typical rising and falling of CK, CK-MB, LDH, or AST activities along
with clinical and electrocardiographic features [6,7].
The need to ﬁndmoleculeswith higher sensitivity and speciﬁcity for
the diagnosis of AMI and the development of newmethods of detection
made the emergence of cardiac troponins (cTn) possible at the end of
1980s [8]. A newerawas born in the diagnosis of AMI because of its clin-
ical sensitivity and myocardial-speciﬁcity, placing cTn as ﬁrst-line bio-
markers in the deﬁnition of ACS. Medical community moved from a
clinical–electrocardiographic–biochemical approach to AMI deﬁnition
to a biomarker-centered deﬁnition in which cTn have a central role [9].
3. Biomarkers in current standard of care
3.1. Troponins
Troponins are cardiac proteins important for actin andmyosin inter-
action, modulating sarcomeric contractile function in response to cyto-
solic calcium and protein phosphorylation. The troponin complex is
composed of three regulatory proteins: cTnC, cTnI, and cTnT [10].C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Causes of acute elevation of troponin in the absence of ACS.
Causes of acute elevation of troponin in absence of ACS




Acute heart failure Acute aortic dissection
Radiofrequency catheter ablation Sepsis
Cardiac contusion Subarachnoid
hemorrhage
Left ventricular hypertrophy Acute lung edema
Cardiac Amyloidosis Pulmonary hypertension
Electrical cardioversion Chronic kidney disease
Heart surgery Strenuous exercise
Percutaneous coronary intervention Sympathomimetic drugs
Heart transplantation Chemotherapy
Coronary vasospasm






21D. del Val Martin et al. / IJC Metabolic & Endocrine 8 (2015) 20–23Troponins T and I have unique cardiac isoforms,whereas cardiacmuscle
and skeletal muscle share troponin C isoforms, rendering this protein
unsuitable for diagnostic use. Troponins T and I are currently the gold
standard for the detection of myocardial injury and are key to clinical
decision making in ACS [11–14].
The Third Universal Deﬁnition of Myocardial Infarction requires a
detection of a typical rise and fall in serum cTn with at least one value
above the 99th percentile of the upper reference limit (URL) and with
at least one of the following: (I) Symptoms of ischemia, (II) new or pre-
sumed new signiﬁcant ST-segment–T wave (ST–T) changes or new left
bundle branch block (LBBB), (III) development of pathological Qwaves,
(IV) imaging evidence of new loss of viablemyocardium or new region-
al wall motion abnormality, and (V) identiﬁcation of an intracoronary
thrombus by angiography or autopsy. Values of cTn should bemeasured
with a coefﬁcient of variation of 10% or less [15].
The detection of abnormal cTn levels after myocardial injury occurs
generally 2–4 h after the initial insult. The development of what is
known as high-sensitivity assays has increased the sensitivity of cTn in
the ﬁrst few hours after coronary occlusion. It is possible that early,
small and non-sustainable releases of cTn represent reversible injury
mobilizing cytosolic or free cTn, while continuous and severe damage
inducing cell death provokes membrane rupture with liberation of a
structurally bound pool with longer detection periods. This concept
could explain why brief episodes of ischemia, tachyarrhythmias, heart
failure, takotsubo syndrome and even induction of mental stress can in-
duce variable amounts of cTnI release.
The crucial role of cTn in the routine assessment of suspected myo-
cardial infarction goes beyond diagnostic purposes. Elevation of cTn
levels is an important independent prognostic marker as shown in sev-
eral clinical trials and one meta-analysis [16–18]. Moreover, cTn is key
in determining the choice of invasive or conservative strategies after
ACS. The TACTICS-TIMI-18 trial enrolled 2200 patients with non-ST ele-
vation myocardial infarction that were randomly assigned to an early
invasive, with routine coronary angiography within the ﬁrst 48 h or a
more conservative approach, with only ischemia-driven revasculariza-
tion. Abnormal cTnI helped to deﬁne the subgroup of patients who
had a greater beneﬁt from an early invasive management [19].
The deﬁnition of high-sensitivity cTn is not clearly established, but
last generation assays can detect cTn in approximately 95% of normal
individuals. Moreover, high-sensitivity cTn levels appear to be indepen-
dent prognostic markers in elderly individuals and stable coronary ar-
tery disease [20–22]. Ongoing and future studies will help to establish
whether cTn will move from a diagnostic tool almost exclusive of the
acute setting to a valuable prognostic test also in ofﬁce consultation.
Although cTn, especially cTnI, is highly speciﬁc for myocardial dam-
age, they are not able to discern between ischemic or inﬂammatory or
traumatic injury. Furthermore, there are several situations associated
with cTn release that are not related to ACS (Table 1) [23].
3.2. C-reactive protein (CRP)
Inﬂammation pathways play an important role in the pathogenesis
of atherothrombosis and ACS [24]. CRP is an acute-phase inﬂammatory
reactant marker that has been extensively studied as indicative of a
higher cardiovascular risk among patients with established atheroscle-
rosis. Ridker P et al. suggested that plasma concentration of CRP predicts
the risk of future myocardial infarction and stroke [25]. Importantly,
statins are capable of reducing CRP beyond cholesterol-lowering prop-
erties [26] and CRP could be a useful test to reclassify individuals consid-
ered at intermediate-risk for future cardiovascular complications.
ACS are commonly associated with elevated levels of CRP, probably
reﬂecting widespread vascular inﬂammation. Several studies in non-
ST elevationmyocardial infarction have found that increased CRP values
are independent prognostic markers of recurrent nonfatal myocardial
infarction or cardiac death (GUSTO IV, PROVE IT-TIMI 22) [27,28]. In
ST-elevation myocardial infarctions it might reﬂect the extent ofmyocardial injury. Despite some positive results, CRP has not been
shown to be an independent predictor of events in all studies [29–31].
Given the current treatment of ACS, including double antiplatelet
therapy, high intensity statin treatment and optimal revascularization
strategies, the role of CRP in the routine prognostic assessment of ACS
is not clear.
3.3. Cystatin-C
Cystatin C is a cysteine protease inhibitor involved in the catabolism
of proteins. This protein is synthesized in all nucleated cells at a constant
rate, and is freely ﬁltered by the glomerulus with no reabsorption into
the blood [32]. Although creatinine is the most used biomarker for the
estimation of glomerular function, cystatin C is less inﬂuenced by
other factors like diet, muscle mass, or body constitution [33]. Several
studies have shown that cystatin C is more sensitive in identifying
mild reductions of renal function than creatinine levels [34].
It is widely recognized that patients with renal impairment have a
higher prevalence of cardiovascular disease with an associated higher
mortality [35]. Considering the known prognostic impact of poor renal
function in acute coronary syndrome patients, it seems reasonable to
hypothesize that early stages of kidney dysfunctionwould provide addi-
tional prognostic information. Jernberg T. et al. were the ﬁrst to demon-
strate that measurement of cystatin-C substantially improves the early
risk stratiﬁcation of a large population with suspected or conﬁrmed
non-ST elevation ACS [36]. More recent studies conﬁrm that cystatin-C
concentration is independently correlated with cardiovascular risk,
including myocardial infarction and cardiovascular death [37,38].
The utility of cystatin-C, instead of other renal function estimators, as
a prognostic biomarker has been emerging in the past few years.
However, it should bemore fully explored in awide spectrum of clinical
scenarios, with current management strategies, before it becomes
routine assessment.
4. Promising biomarkers in ACS
4.1. Copeptin
Copeptin is the C-terminal fragment of vasopressin precursor hor-
mone (CT-proAVP) and is released together with vasopressin during
precursor processing. The measurement of copeptin seems to be a clin-
ically relevant method of reliably assessing AVP plasma concentrations,
which cannot be determined directly in routine practice [39].
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marker. Keller et al. tested whether determination of copeptin added
diagnostic information to cardiac troponin in the early evaluation of pa-
tients with suspected myocardial infarction. In this study they analyzed
levels of copeptin, cTnT, myoglobin, and creatine kinase-myocardial
band, after 3 and 6 h of 1386 patients with suspected ACS. The results
were that combined measurement of copeptin and cTnT on admission
improved the sensibility of diagnosis of acute myocardial in the overall
population and the combination of copeptin with a conventional cTnT
provided a negative predictive value of 92.4% [40].
Results of the CHOPIN trial (Copeptin Helps in the early detection Of
Patients with acute myocardial INfarction), have shown that adding
copeptin to cTnI allowed safe rule out of AMI with a negative predictive
value N99% in patients presenting early with a suspected ACS. In addi-
tion, the study suggests that the combination of abnormal copeptin
and cTnI was an independent predictor of death at 180 days [41]. In
the same line, Mockel M. et al. have demonstrated that patients who
were troponin negative and also copeptin negative, using the initial
blood sample, had virtually the same risk of having amajor adverse car-
diac event within 30 days (5.46%) as patients undergoing conventional
serial blood samples to rule out myocardial infarction (5.50%) [42].
In conclusion, emerging data suggests that copeptin could provide
additional value to cTn in the early rule-out patients presenting with
suspected ACS.
4.2. Growth differentiation factor 15 (GDF-15)
GDF-15 is amember of the transforming growth factor beta cytokine
superfamily that under physiologic conditions is only expressed by the
placenta. GDF-15 plasma levels increase in response to stress and in-
ﬂammation and it is involved in regulating apoptotic pathways needed
for development, differentiation and tissue repair [43]. Focusing on the
heart, GDF-15 is induced in the myocardium tissue after ischemia and
for this reason it has been proposed as a biomarker of myocardial injury
[44].
Several studies suggest that GDF-15 may be useful to risk stratiﬁca-
tion of patients presenting with symptoms of ACS. Schaub N et al. mea-
sured GDF-15, hs-cTn and BNP in 646 patients presenting to the
emergency department with chest pain. GDF-15 predicted all-cause
mortality independently and more accurately than hs-cTn and BNP
[45]. Widera C. et al. determined that a single measurement of GDF-15
on admission of patientswithNSTE-ACSmarkedly enhanced the predic-
tive value of GRACE score [46].
Importantly, GDF-15 may be an important tool for identifying those
patients that would beneﬁt the most from an early invasive strategy in
non-ST elevation-ACS. Wollert KC. et al., in a subgroup of FRagmin and
Fast Revascularization during InStability in Coronary artery disease II
(FRISC-II) trial, examined GDF-15 and other biomarkers and clinical pa-
rameters in patients included in. Patients presentingwith highly elevat-
ed levels of GDF-15 (N1800 ng/l) in combination with cTn beneﬁted
from an invasive therapeutic strategy, while patients with lower levels
of GDF-15 (b1200 ng/l) did not, even when presenting with ST-
depression or cTnT N0.01 μg/L. Furthermore, elevated levels of GDF-15
were shown to be a strong independent predictor of death or recurrent
myocardial infarction in patients treated with a conservative strategy
instead of an invasive one. [47,48].
Although current data supports the potential role of GDF-15 as a di-
agnostic and prognostic biomarker in ACS, further prospective and ran-
domized trials with contemporary treatment are needed to conﬁrm
these data.
4.3. Micro-RNAs
MicroRNAs (miRNAs) are non-coding RNA fragments of around 22
nucleotides with a key role in the regulation of mRNA coding for key
proteins in the maintenance of cell integrity [49]. Over the past years,miRNAs have been postulated as important markers of different patho-
logic states, particularly the development of cancer-related processes
[50,51]. Over 700 different human miRNAs have been described, al-
though only a fewof themhave beendetected and analyzed in AMI [52].
Myocardial infarction, as a damage and cell death process, sets in
motion a number of genetic processes that aim repair and survival of
the cardiomyocyte. Therefore, it seems intuitive to suggest that there
would be changes in circulating levels of miRNA in the ﬁrst few hours
after beginning of symptoms and that it could be an extremely sensitive
marker of AMI. van Rooij et al. described changes in miRNA expression
in murine models during AMI [53]. More recently, D'Alessandra et al.
analyzed plasma levels of miR-1, -133a, -133b, -499-5p, -122 and
-375, in 17 healthy donors and 33 STEMI patients within few hours
after the onset of myocardial infarction symptoms. Levels of miR-1,
-133a, -133b, and miR-499-5p experienced a clear increase in the
hours following infarction, while miR-122 and miR-375 experienced a
drop in their plasma levels [54].
Up to date, approximately 20miRNAs have been proposed as poten-
tial biomarkers of ACS. However, many of the studies have been carried
out with small sample sizes and heterogeneous populations, leading to
different results. Although miRNAs are promising candidates to an
important role in the early diagnosis of myocardial infarction, more
research is needed to determine its accuracy as a cardiac biomarker
and its possible application in routine clinical practice.
5. Conclusion
Several biomarkers have been proposed as useful candidates to con-
tribute to cTn as relevant tools for the diagnosis and risk stratiﬁcation of
myocardial infarction. The ideal biomarker should provide increased
sensitivity especially over the ﬁrst 3 h after onset of symptoms, greater
precision regarding mechanisms of cardiomyocyte injury and sufﬁcient
prognostic information as to guide clinicians to the best management
strategy. Until now, none of these novel biochemical tests is ready for
prime time in routine clinical practice, but copeptin could be considered
complementary to cTn for a rapid rule-out of patients presenting with
compatible ACS symptoms. CRP or BNP values are more widely avail-
able, but despite providing additional reﬁnement in risk stratiﬁcation,
it is doubtful that clinicians need its routine determination beyond
traditional risk factors, medical history, electrocardiogram, cTn, stress
test and coronary angiography. However, future studies should address
possible contributions of these novel biomarkers and new advances in
knowledge of myocardial damage and atherothrombotic pathways are
eagerly awaited.
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